Marker Therapeutics Inc [MRKR] stock is trading at $1.56, up 28.93%. An important factor to consider is whether the stock is rising or falling in short-term value. The MRKR shares have gain 38.05% over the last week, with a monthly amount glided 31.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Marker Therapeutics Inc [NASDAQ: MRKR] stock has seen the most recent analyst activity on March 05, 2025, when Canaccord Genuity initiated its Buy rating and assigned the stock a price target of $8. Previously, Piper Sandler started tracking the stock with Overweight rating on March 25, 2021, and set its price target to $6. On March 19, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $6 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2.50 on May 12, 2020. ROTH Capital initiated its recommendation with a Buy. In a note dated December 03, 2018, Piper Jaffray upgraded an Overweight rating on this stock.
Marker Therapeutics Inc [MRKR] stock has fluctuated between $0.95 and $5.99 over the past year. Marker Therapeutics Inc [NASDAQ: MRKR] shares were valued at $1.56 at the most recent close of the market.
Analyzing the MRKR fundamentals
Marker Therapeutics Inc [NASDAQ:MRKR] reported sales of 5.70M for the trailing twelve months, which represents a drop of -71.94%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -2.31%, Pretax Profit Margin comes in at -2.24%, and Net Profit Margin reading is -2.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.75, Equity is -1.02 and Total Capital is -0.91.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2318 points at the first support level, and at 0.9035 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8541, and for the 2nd resistance point, it is at 2.1481.
Ratios To Look Out For
For context, Marker Therapeutics Inc’s Current Ratio is 6.79. On the other hand, the Quick Ratio is 6.79, and the Cash Ratio is 5.47. Considering the valuation of this stock, the price to sales ratio is 3.10, the price to book ratio is 1.21.
Transactions by insiders
Recent insider trading involved ELMS STEVE, Director, that happened on Dec 23 ’24 when 11085.0 shares were purchased. 10% Owner, New Enterprise Associates 16, completed a deal on Dec 23 ’24 to buy 0.55 million shares.
